Loading..
  • Oasmia logo
  • Oasmia logo
  • About Us
  • Our Science
  • Corporate Governance
  • Investors
  • Media
  • Contact
  • About Us
    • Purpose, Vision & Mission
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Collaborations and partners
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Our Science
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Portfolio
      • Docetaxel Micellar
      • XR-19
    • Animal Health
    • Research and development
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Investment case
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Contact
  • Contact

Press releases

All releases
  • Regulatory Releases
  • Press Releases
2013
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2012
  • 2011
  • All years
Non Regulatory
December 5, 2013

Interim report for the period May – October 2013

Non Regulatory
December 3, 2013

Oasmia Announces Successful FDA Pre-Approval Inspection of Its Manufacturing Facility

Regulatory
December 2, 2013

Nexttobe extends loan to Oasmia

Non Regulatory
October 2, 2013

Communiqué from Annual General Meeting 2013

Non Regulatory
September 11, 2013

Oasmia’s two major shareholders nominate Alexander Kotsinas to new board member

Non Regulatory
September 6, 2013

Interim report for the period May – July 2013

Non Regulatory
August 28, 2013

Notice of Annual General Meeting

Non Regulatory
August 22, 2013

The Oasmia Pharmaceutiacal Annual Report is now published

Non Regulatory
June 13, 2013

Oasmia appoints new Vice President Communications

Non Regulatory
June 7, 2013

Year-end report for the fiscal year May 2012 – April 2013

Non Regulatory
May 28, 2013

Oasmia’s patented XR-17 technology generates novel cancer combination therapy

Non Regulatory
May 6, 2013

Oasmia initiates clinical program with Paclical® in metastatic breast cancer

Non Regulatory
March 1, 2013

Interim report for the period May 2012 – January 2013

Non Regulatory
February 11, 2013

Oasmia Pharmaceutical strengthens its management team

Non Regulatory
February 4, 2013

Oasmia signs marketing and distribution agreement for product candidate Paclical® in Russia and CIS countries

Non Regulatory
January 15, 2013

Nexttobe increases their ownership in Oasmia

Non Regulatory
January 7, 2013

Oasmia Pharmaceutical AB and Abbott Sign Global Collaboration Agreement for Canine Oncology Therapies

Investor contact

Cord Communications
IR@oasmia.com
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Contact
Oasmia logo
  • About Us
  • Our Science
  • Corporate Governance
  • Investors
  • Media
  • Contact

Oasmia Pharmaceutical AB develops, manufactures, markets and sells an improved generation of drugs within human and veterinary oncology. Product development aims to produce novel formulations of well-established cytostatic agents which show improved performance, an improved side-effect profile and a wider range of therapeutic areas compared with existing alternatives. Product development is based on the proprietary technology platform XR-17.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Oasmia Pharmaceutical AB
Vallongatan 1, 752 28
Uppsala, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@oasmia.com